Healthcare Facilities company Global Health announced Q2FY25 results Financial Highlights: Total income of Rs 9,748 million, growth of 12.7% YoY and 10.4% QoQ. EBITDA was Rs 2,465 million, growth of 5.5% YoY and 18.4% QoQ. EBITDA margins were at 25.3% in Q2FY25. Profit after tax was Rs 1,308 million, growth of 4.5% YoY and 23.1% QoQ. PAT margins were 13.4% compared to 14.5% in Q2FY24. Net cash surplus of Rs 7,186 million at the end of 30th September, 2024. During the quarter, 52 bed were added at Lucknow and 66 beds at Patna resulting in total bed addition of 118 beds in Q2FY25. Average occupied bed days increased by 9.1% YoY, with strong occupancy of 64.3% on increased bed capacity. In-patients count increased by 8.8% YoY; Out-patients count increased by 6.6% YoY. ARPOB marginally grew by 1.9% YoY to Rs 62,140 in Q2FY25 due to combination of tariff increase in Matured facility and change in case mix across the group. Matured hospitals revenue was Rs 6,882 million, strong growth of 13.5% YoY and 7.8% on QoQ basis. EBITDA was Rs 1,739 million, growth of 12.5% YoY and 9.4% on QoQ basis. Developing hospitals revenue was Rs 2,754 million, growth of 4.2% YoY and 16.2% on QoQ basis. EBITDA was Rs 823 million, down by 8.2% YoY and strong growth of 41.7% on QoQ basis. During the quarter, International Patients Revenue was Rs 513 million. Out-patient pharmacy (Hospital + Retail) continues to register strong growth. Revenue increased by 24.5% from Rs 298 million in Q2FY24 to Rs 371 million in Q2FY25. Other Highlights: During the quarter, 52 bed were added at Lucknow and 66 beds at Patna resulting in total bed addition of 118 beds. 25 doctors on-boarded across facilities to further strengthen clinical capability. New Da Vinci Xi robot introduced in Lucknow and additional Da Vinci Xi robot operationalized in Gurugram. Medanta Gurugram performed its first CAR-T Cell therapy, an advanced cancer treatment that harnesses the power of the patient’s own immune system to fight cancer. Medanta Gurugram achieves significant milestone of completing 3,000 kidney transplants. Medanta Lucknow completes 100 breast cancer surgeries. Medanta Gurugram doctors successfully performed bilateral lung transplant in a patient with ILD and complex autoimmune condition. Medanta Gurugram doctors uses minimally invasive unique approach to treat rare heart condition idiopathic chylopericardium. Complex and severe genetic disorder Wiskott Aldrich Syndrome cured at Medanta Gurugram using half-match stem cell transplant. Pankaj Sahni, Group CEO and Director, said: “We are pleased to report a strong performance this quarter, achieving our highest-ever quarterly Revenue and EBITDA. Growth momentum was robust across our network hospitals, as we continue to invest in cutting-edge technologies, enhance clinical capabilities through the on-boarding of senior clinicians, and expand our network by adding more beds. I am also excited to announce that Medanta has recently signed an Operations and Management agreement to operate and manage a state-of-the-art, 750-bed super-specialty hospital in Pitampura, New Delhi. The hospital will be jointly built by Medanta and our partners Dr. Narayan Dutt Shirmali Foundation International Charitable Trust Society. This expansion reinforces our vision of creating a high-quality healthcare delivery platform, strengthens our presence in Delhi/NCR, and underscores our commitment to elevating patient care in the region through world-class services and infrastructure.” Result PDF